Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Taube · SciRah

Researcher profile · Semantic Scholar

J. Taube

Share profile

J. Taube — researcher profile on SciRah

h-index: 77
Works: 278
Citations: 48K

Most-cited papers

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
P. Forde, J. Spicer, Shun Lu, M. Provencio +25 more
2022New England Journal of Medicine2,230 citations Open access
Semantic Scholar
Neoadjuvant checkpoint blockade for cancer immunotherapy
S. Topalian, J. Taube, D. Pardoll
2020Science922 citations Open access
Semantic Scholar
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
J. Caushi, Jiajia Zhang, Zhi-Cheng Ji, A. Vaghasia +51 more
2021Nature486 citations Open access
Semantic Scholar
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
H. Kluger, H. Tawbi, M. Ascierto, M. Bowden +21 more
2020Journal for ImmunoTherapy of Cancer283 citations Open access
Semantic Scholar
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma
N. Gross, D. Miller, N. Khushalani, V. Divi +25 more
2022New England Journal of Medicine255 citations Open access
Semantic Scholar
The Society for Immunotherapy in Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
J. Taube, Guray Akturk, Michael Angelo, Elizabeth L. Engle +23 more
2020Journal for ImmunoTherapy of Cancer237 citations Open access
Semantic Scholar
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial.
S. Topalian, S. Bhatia, A. Amin, R. Kudchadkar +20 more
2020Journal of Clinical Oncology218 citations Open access
Semantic Scholar
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.
R. Amaria, A. Menzies, E. Burton, R. Scolyer +80 more
2019The Lancet Oncology206 citations Open access
Semantic Scholar
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial
R. Ferris, W. Spanos, R. Leidner, A. Gonçalves +15 more
2021Journal for ImmunoTherapy of Cancer203 citations Open access
Semantic Scholar
Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study
Erika J. Lampert, A. Zimmer, M. Padget, A. Cimino-Mathews +14 more
2020Clinical Cancer Research180 citations Open access
Semantic Scholar
Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade
S. Berry, Nicolas A. Giraldo, B. Green, T. Cottrell +33 more
2021Science174 citations Open access
Semantic Scholar
Multiplex Immunohistochemistry and Immunofluorescence: A Practical Update for Pathologists.
P. Harms, T. Frankel, M. Moutafi, Arvind Rao +5 more
2023Modern Pathology164 citations
Semantic Scholar
Interleukin-36γ–producing macrophages drive IL-17–mediated fibrosis
S. Sommerfeld, Chris C. Cherry, Remi M. Schwab, Liam Chung +10 more
2019Science immunology151 citations Open access
Semantic Scholar
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
J. Reuss, V. Anagnostou, T. Cottrell, Kellie N. Smith +28 more
2020Journal for ImmunoTherapy of Cancer146 citations Open access
Semantic Scholar
Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade
J. Stein, E. Lipson, T. Cottrell, P. Forde +11 more
2019Clinical Cancer Research146 citations Open access
Semantic Scholar
Compartmental analysis of T cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer
Jiajia Zhang, Zhi-Cheng Ji, J. Caushi, M. El Asmar +27 more
2019Clinical Cancer Research127 citations Open access
Semantic Scholar
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
J. Brahmer, C. Drake, I. Wollner, J. Powderly +16 more
2023Journal of Clinical Oncology126 citations
Semantic Scholar
Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma
Daniel H. Shu, W. Ho, L. T. Kagohara, Alexander A. Girgis +35 more
2024Nature Immunology125 citations
Semantic Scholar
PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function
S. Whelan, E. Ophir, M. Kotturi, O. Levy +16 more
2019Cancer immunology research125 citations Open access
Semantic Scholar
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
P. Nghiem, S. Bhatia, E. Lipson, W. Sharfman +25 more
2021Journal for ImmunoTherapy of Cancer118 citations Open access
Semantic Scholar
Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study
J. Taube, K. Roman, Elizabeth L. Engle, Chi-Chung Wang +12 more
2021Journal for ImmunoTherapy of Cancer94 citations Open access
Semantic Scholar
Lung tumor–infiltrating Treg have divergent transcriptional profiles and function linked to checkpoint blockade response
Arbor G. Dykema, Jiajia Zhang, Laurene S. Cheung, S. Connor +35 more
2022bioRxiv73 citations Open access
Semantic Scholar
Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma
Michael A. Gorin, H. Patel, S. Rowe, N. Hahn +11 more
2021European Urology Oncology72 citations Open access
Semantic Scholar
Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.
J. Stein, Abha Soni, L. V. Danilova, T. Cottrell +9 more
2019Annals of Oncology72 citations Open access
Semantic Scholar
Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma
V. Anagnostou, D. Bruhm, N. Niknafs, J. White +20 more
2020Cell Reports Medicine69 citations Open access
Semantic Scholar
Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
S. Rosner, J. Reuss, M. Zahurak, Jiajia Zhang +13 more
2023Clinical Cancer Research60 citations Open access
Semantic Scholar
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
A. Pavlick, C. Ariyan, Elizabeth I. Buchbinder, D. Davar +19 more
2023Journal for ImmunoTherapy of Cancer58 citations Open access
Semantic Scholar
INTRATUMORAL ADAPTIVE IMMUNOSUPPRESSION AND TYPE 17 IMMUNITY IN MISMATCH REPAIR PROFICIENT COLORECTAL TUMORS
Nicolas J. Llosa, Brandon S. Luber, Ada J. Tam, Kellie N. Smith +20 more
2019Clinical Cancer Research57 citations Open access
Semantic Scholar
Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas
F. Succaria, P. Kvistborg, J. Stein, Elizabeth L. Engle +9 more
2020Cancer Immunology and Immunotherapy41 citations Open access
Semantic Scholar
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
Kellie N. Smith, Nicolas J. Llosa, T. Cottrell, Nicholas M. Siegel +37 more
2019Journal of Immunotherapy for Cancer41 citations Open access
Semantic Scholar
Quantitative Characterization of CD8+ T Cell Clustering and Spatial Heterogeneity in Solid Tumors
Chang Gong, R. Anders, Qing-Feng Zhu, J. Taube +6 more
2019Frontiers in Oncology38 citations Open access
Semantic Scholar
New interpretable machine-learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy
Evan Greene, G. Finak, Leonard D'Amico, N. Bhardwaj +8 more
2021Patterns34 citations Open access
Semantic Scholar
Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma
Amy K. Kim, Faiz Gani, Andrew J. Layman, S. Besharati +12 more
2019Cancer immunology research30 citations Open access
Semantic Scholar
Increased Expression of PD-1 and PD-L1 in Patients With Laryngotracheal Stenosis
Ruth J. Davis, Ioan A. Lina, D. Ding, Elizabeth L. Engle +3 more
2020The Laryngoscope29 citations Open access
Semantic Scholar
Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer
D. Rimm, Gang Han, J. Taube, E. Yi +7 more
2019Breast Cancer Research28 citations Open access
Semantic Scholar
Expression of programmed cell death-ligand 1 and associated lymphocyte infiltration in olfactory neuroblastoma.
N. London, L. Rooper, J. Bishop, Haiying Xu +7 more
2019World Neurosurgery27 citations
Semantic Scholar
Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma
J. Deutsch, E. Lipson, L. Danilova, S. Topalian +11 more
2023Cell Reports Medicine26 citations Open access
Semantic Scholar
Multiplex immunohistochemical phenotyping of T cells in primary prostate cancer
Busra Ozbek, Onur Ertunç, A. Erickson, I. Vidal +8 more
2021medRxiv21 citations Open access
Semantic Scholar
P1.18-02 The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC
J. Heymach, J. Taube, T. Mitsudomi, D. Harpole +5 more
2019Journal of Thoracic Oncology21 citations Open access
Semantic Scholar
Spatial UMAP and image-cytometry for topographic immuno-oncology biomarker discovery
Nicolas A. Giraldo, S. Berry, E. Becht, D. Ateş +15 more
2021Cancer immunology research19 citations Open access
Semantic Scholar
Evaluating T-cell cross-reactivity between tumors and immune-related adverse events with TCR sequencing: pitfalls in interpretations of functional relevance
T. Cottrell, Jiajia Zhang, Boyang Zhang, G. Kaunitz +9 more
2021Journal for ImmunoTherapy of Cancer19 citations Open access
Semantic Scholar
Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma
R. Dummer, C. Robert, R. Scolyer, J. Taube +15 more
2023Cancer Research17 citations
Semantic Scholar
Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapy
T. McMiller, S. Besharati, M. Yarchoan, Qing-Feng Zhu +9 more
2024Journal for ImmunoTherapy of Cancer16 citations
Semantic Scholar
Quantitative Assessment of the Immune Microenvironment in Patients With Iatrogenic Laryngotracheal Stenosis
Ruth J. Davis, Ioan A. Lina, B. Green, Elizabeth L. Engle +5 more
2020Otolaryngology Head & Neck Surgery16 citations Open access
Semantic Scholar
Whole Slide Imaging, Mutual Information Registration (WSIMIR) For Multiplex Immunohistochemistry and Immunofluorescence
Joshua Doyle, B. Green, M. Eminizer, Daniel Jiménez-Sánchez +11 more
2023Laboratory investigation; a journal of technical methods and pathology15 citations
Semantic Scholar
Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee
A. Monette, Sarah Warren, J. C. Barrett, Charlie Garnett-Benson +4 more
2024Journal for ImmunoTherapy of Cancer14 citations Open access
Semantic Scholar
Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures
Laurene S. Cheung, Lingling Chen, Teniola F Oke, T. Schaffer +13 more
2021Journal for ImmunoTherapy of Cancer14 citations Open access
Semantic Scholar
Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)
S. Berry, Nicolas A. Giraldo, Peter Nguyen, B. Green +87 more
2019Journal of Immunotherapy for Cancer14 citations Open access
Semantic Scholar
Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).
G. Long, J. Kirkwood, C. Hoeller, J. Grob +16 more
2023Journal of Clinical Oncology12 citations
Semantic Scholar
Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
J. Caushi, Jiajia Zhang, Zhi-Cheng Ji, A. Vaghasia +51 more
2021Nature12 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Pardoll×17
Invite
D. Pardoll — researcher profile on SciRah
S. Topalian×14
Invite
S. Topalian — researcher profile on SciRah
Elizabeth L. Engle×11
Invite
Elizabeth L. Engle — researcher profile on SciRah
J. Stein×11
Invite
J. Stein — researcher profile on SciRah

×10

Invite

T. Cottrell — researcher profile on SciRah

Invite

P. Forde — researcher profile on SciRah

Invite

J. Brahmer — researcher profile on SciRah

Kellie N. Smith×9

Invite

Kellie N. Smith — researcher profile on SciRah

V. Anagnostou×8

Invite

V. Anagnostou — researcher profile on SciRah

Invite

E. Lipson — researcher profile on SciRah

Jiajia Zhang×7

Invite

Jiajia Zhang — researcher profile on SciRah

Invite

Ada J. Tam — researcher profile on SciRah